羅欣藥業(yè)與印度阿拉賓度制藥達成戰(zhàn)略合作，在華共建合資企業(yè)引進高質(zhì)量低價格藥品

發(fā)布時間：2018年12月25日 瀏覽次數(shù)：

分享：

2018年12月23日，上海 -- 山東羅欣藥業(yè)股份有限公司（以下簡稱“羅欣藥業(yè)”）宣布公司與印度阿拉賓度制藥有限公司（Aurobindo Pharma，以下簡稱“阿拉賓度制藥”）簽訂戰(zhàn)略合作協(xié)議，雙方將共同在中國設(shè)立合資公司，聯(lián)合投資研發(fā)和生產(chǎn)體系以引進呼吸領(lǐng)域產(chǎn)品。阿拉賓度制藥將通過合資公司把更多具有技術(shù)壁壘的呼吸領(lǐng)域產(chǎn)品及技術(shù)轉(zhuǎn)移到中國，并且實現(xiàn)本地化生產(chǎn)；合資公司將擁有眾多已在美國以及歐洲獲取上市批件的產(chǎn)品，未來將持續(xù)給中國、美國及歐洲市場供貨，為三地的患者帶來更多更好的用藥選擇。

Shanghai, China - Dec, 23 2018 -- Shandong Luoxin Pharmaceutical Group (hereinafter referred to as "Luoxin Pharmaceutical") today announced the company has reached an agreement with Aurobindo Pharma Co., Ltd. (hereinafter referred to as "Aurobindo Pharma") to establish a joint venture company in China and invest in both R&D and manufacturing systems on respiratory products. Aurobindo Pharma will transfer respiratory products and technical know-hows with technologic barriers to China for local manufacturing; the joint venture company will possess numerous products approved by US FDA and EMA, and manufacture respiratory products to supply China, US and EU markets to provide more and better options for patients in those regions. 

阿拉賓度制藥是全球前五大仿制藥制藥公司，1992年在印度上市。公司具備非常強健的產(chǎn)品線，主要專注于呼吸系統(tǒng)、中樞神經(jīng)系統(tǒng)、心血管系統(tǒng)、消化系統(tǒng)、抗感染、抗逆轉(zhuǎn)錄病毒（HIV）、糖尿病和抗過敏等治療領(lǐng)域。公司產(chǎn)品擁有優(yōu)異的質(zhì)量和有競爭力的成本，銷售涵蓋美國、歐洲、新興市場等150多個國家，具備很強的產(chǎn)品供應(yīng)能力。通過自身的研發(fā)能力，阿拉賓度制藥迅速在全球范圍內(nèi)申請專利、DMFs、ANDAs和仿制藥技術(shù)資料，目前是印度DMFs備案和ANDAs申報最多的仿制藥企業(yè)。阿拉賓度制藥多數(shù)工廠都通過了美國FDA和歐盟COS 認證，使其產(chǎn)品不斷向著高技術(shù)、高附加值和高端市場邁進。今年9月，阿拉賓度收購了仿制藥巨頭山德士在美國的業(yè)務(wù)，使其成為美國市場第二大仿制藥企業(yè)。

Aurobindo Pharma, a publicly listed company in India since 1992, is a top 5 generic pharmaceutical company globally. The company boasts a strong R&D pipeline focused on respiratory, central nerve system, cardiovascular, gastrointestinal track, anti-infectious, anti-HIV, diabetes, and other therapeutic areas. The products are of high quality, affordability and supply-chain sustainability, and have been sold in more than 150 countries across US, EU and emerging markets. The company has the most DMF and ANDA applications among all India generic companies, and many of its manufacturing sites are FDA and COS certified. The company acquired the commercial operations in the US from Sandoz in September this year, making it the second largest generic company in US.  

中國目前存在非常大的未滿足的臨床需求。最近國家醫(yī)療保障局主導的“4+7”試點聯(lián)合采購政策啟動后，能夠為廣大患者提供更高質(zhì)量、更低價格的產(chǎn)品顯得尤為重要。近期國家關(guān)于優(yōu)化藥品注冊審評審批以及接受藥品境外臨床實驗數(shù)據(jù)的政策，給國際優(yōu)質(zhì)藥品進入中國創(chuàng)造了更加便利的條件。在國際市場范圍內(nèi)，印度制藥企業(yè)具有非常強的質(zhì)量和成本競爭優(yōu)勢，羅欣藥業(yè)與阿拉賓度制藥的牽手因而具有重要的戰(zhàn)略意義。羅欣藥業(yè)將繼續(xù)借助多年的對外合作經(jīng)驗，致力于把更多優(yōu)秀的國際產(chǎn)品和技術(shù)落地，為中國患者帶來更多更好的產(chǎn)品選擇，并為降低國家醫(yī)療費用支出貢獻自己的力量。

China still faces enormous unmet medical needs. After the recent implementation of ‘4+7 Quantity Procurement’ policy enacted by the central government, it is of paramount importance to provide patients with high quality and affordable medicines.  The recent new regulations on expediting regulatory processes and acceptance of overseas clinical study data have a positive impact on bringing high quality pharmaceutical products from overseas into China market. Under these circumstances, the collaboration between Luoxin and Aurobindo is of great strategic importance given the competiveness of Indian pharmaceutical companies in terms of quality and cost. Luoxin Pharma will continue to utilize its rich experience in external collaboration and bring more high quality products into China, thus benefiting the patients and helping alleviate the medical expense burden.  

羅欣藥業(yè)執(zhí)行董事長劉振騰表示：“羅欣藥業(yè)非常重視與以阿拉賓度制藥為代表的國際仿制藥巨頭公司的合作，我們一方面期待與阿拉賓度進一步探討更多產(chǎn)品及商業(yè)模式的合作，同時也希望與更多優(yōu)秀的國內(nèi)外企業(yè)合作，利用羅欣藥業(yè)多年建立起來的全產(chǎn)業(yè)鏈優(yōu)勢，通過資源整合實現(xiàn)多方共贏的模式，為合作伙伴賦能，最終讓中國的老百姓、中國醫(yī)藥市場以及國家受益。”

Mr. Ryan Liu, the Executive Chairman of Luoxin Pharma said, “Luoxin highly values the collaboration with Aurobindo. While we expect to hold further discussions with Aurobindo on products and business models, we look forward to collaborating with more outstanding pharmaceutical companies, domestic and abroad. Our ultimate strategic goal is to achieve win-win situations and energize our partners via Luoxin’s advantages in the whole healthcare value chain established over the years, eventually benefiting the Chinese patients, the Chinese healthcare industry, and the country.”